Quipt Home Medical Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Quipt Home Medical de winst en omzet met respectievelijk 54.1% en 4.3% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 46.1% per jaar.

Belangrijke informatie

54.1%

Groei van de winst

46.1%

Groei van de winst per aandeel

Healthcare winstgroei	58.0%
Inkomstengroei	4.3%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	20 Dec 2024

Recente toekomstige groei-updates

Earnings Release: Here's Why Analysts Cut Their Quipt Home Medical Corp. (TSE:QIPT) Price Target To CA$10.95

Aug 17

Quipt Home Medical Corp. (TSE:QIPT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Feb 17

Recent updates

We Like These Underlying Return On Capital Trends At Quipt Home Medical (TSE:QIPT)

Dec 15

Earnings Release: Here's Why Analysts Cut Their Quipt Home Medical Corp. (TSE:QIPT) Price Target To CA$10.95

Aug 17

Is Quipt Home Medical (TSE:QIPT) A Risky Investment?

Aug 16

Quipt Home Medical Corp.'s (TSE:QIPT) 26% Price Boost Is Out Of Tune With Revenues

Jul 26

Returns At Quipt Home Medical (TSE:QIPT) Are On The Way Up

Jul 17

Investors Aren't Entirely Convinced By Quipt Home Medical Corp.'s (TSE:QIPT) Revenues

Apr 19

Quipt Home Medical Corp. (TSE:QIPT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Feb 17

Earnings Update: Quipt Home Medical Corp. (CVE:QIPT) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Aug 18

Health Check: How Prudently Does Quipt Home Medical (CVE:QIPT) Use Debt?

Jul 13

When Should You Buy Quipt Home Medical Corp. (CVE:QIPT)?

Jun 08

Quipt Home Medical Corp. (CVE:QIPT) Shares Could Be 43% Below Their Intrinsic Value Estimate

Jun 02

Does Protech Home Medical (CVE:PTQ) Have A Healthy Balance Sheet?

May 07

Protech Home Medical Corp. (CVE:PTQ) Could Be Less Than A Year Away From Profitability

Mar 29

Can You Imagine How Elated Protech Home Medical's (CVE:PTQ) Shareholders Feel About Its 331% Share Price Gain?

Feb 22

Calculating The Fair Value Of Protech Home Medical Corp. (CVE:PTQ)

Jan 18

Winst- en omzetgroeiprognoses

TSX:QIPT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2026	268	-1	N/A	N/A	3
9/30/2025	253	-6	N/A	N/A	3
9/30/2024	246	-7	25	35	N/A
6/30/2024	244	-5	30	38	N/A
3/31/2024	241	-4	38	43	N/A
12/31/2023	236	-4	40	47	N/A
9/30/2023	212	-3	30	37	N/A
6/30/2023	189	0	26	34	N/A
3/31/2023	164	2	19	29	N/A
12/31/2022	139	7	17	26	N/A
9/30/2022	128	5	17	26	N/A
6/30/2022	118	2	17	26	N/A
3/31/2022	109	8	15	23	N/A
12/31/2021	99	-10	14	20	N/A
9/30/2021	94	-6	13	18	N/A
6/30/2021	87	-5	13	16	N/A
3/31/2021	81	-14	14	15	N/A
12/31/2020	79	1	13	14	N/A
9/30/2020	73	-4	14	14	N/A
6/30/2020	67	0	19	19	N/A
3/31/2020	62	-6	10	10	N/A
12/31/2019	63	-11	10	10	N/A
9/30/2019	61	-7	8	8	N/A
6/30/2019	57	-27	10	2	N/A
3/31/2019	56	-18	14	11	N/A
12/31/2018	53	-20	10	10	N/A
9/30/2018	55	-7	10	11	N/A
6/30/2018	59	-6	N/A	-4	N/A
3/31/2018	59	-7	N/A	-3	N/A
12/31/2017	61	-4	N/A	-6	N/A
9/30/2017	61	-22	N/A	-5	N/A
6/30/2017	36	-16	N/A	1	N/A
3/31/2017	45	-19	N/A	-8	N/A
12/31/2016	56	-29	N/A	-7	N/A
9/30/2016	73	-28	N/A	-12	N/A
6/30/2016	105	-18	N/A	-9	N/A
3/31/2016	94	-25	N/A	-10	N/A
12/31/2015	73	-16	N/A	-6	N/A
9/30/2015	54	-18	N/A	-2	N/A
6/30/2015	42	-21	N/A	-4	N/A
3/31/2015	30	-7	N/A	3	N/A
12/31/2014	25	-4	N/A	0	N/A
9/30/2014	19	-1	N/A	-1	N/A
6/30/2014	12	0	N/A	0	N/A
3/31/2014	7	-1	N/A	-1	N/A
12/31/2013	5	-2	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat QIPT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat QIPT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat QIPT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van QIPT ( 4.3% per jaar) zal naar verwachting langzamer groeien dan de markt Canadian ( 7.1% per jaar).

Hoge groei-inkomsten: De omzet van QIPT ( 4.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van QIPT naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/22 11:51
Aandelenkoers aan het einde van de dag	2024/12/20 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/09/30

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Quipt Home Medical Corp. wordt gevolgd door 11 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Ishan Majumdar	Baptista Research
Doug Cooper	Beacon Securities Limited
William Sutherland	Benchmark Company

Quipt Home Medical Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 9.9% to CA$9.55

Price target decreased by 14% to CA$10.35

Earnings Release: Here's Why Analysts Cut Their Quipt Home Medical Corp. (TSE:QIPT) Price Target To CA$10.95

Quipt Home Medical Corp. Provides Earnings Guidance for the Year 2024

Price target decreased by 11% to CA$12.00

Quipt Home Medical Corp. (TSE:QIPT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Recent updates

Price target decreased by 9.9% to CA$9.55

Full year 2024 earnings: EPS and revenues miss analyst expectations

We Like These Underlying Return On Capital Trends At Quipt Home Medical (TSE:QIPT)

Quipt Home Medical Corp. to Report Q4, 2024 Results on Dec 16, 2024

Chairman recently bought CA$402k worth of stock

Price target decreased by 14% to CA$10.35

Earnings Release: Here's Why Analysts Cut Their Quipt Home Medical Corp. (TSE:QIPT) Price Target To CA$10.95

Is Quipt Home Medical (TSE:QIPT) A Risky Investment?

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Quipt Home Medical Corp. Provides Earnings Guidance for the Year 2024

New minor risk - Shareholder dilution

Quipt Home Medical Corp. to Report Q3, 2024 Results on Aug 14, 2024

Quipt Home Medical Corp.'s (TSE:QIPT) 26% Price Boost Is Out Of Tune With Revenues

Returns At Quipt Home Medical (TSE:QIPT) Are On The Way Up

Price target decreased by 11% to CA$12.00

Second quarter 2024 earnings released: US$0.032 loss per share (vs US$0.021 loss in 2Q 2023)

Quipt Home Medical Corp. to Report Q2, 2024 Results on May 15, 2024

Investors Aren't Entirely Convinced By Quipt Home Medical Corp.'s (TSE:QIPT) Revenues

Quipt Home Medical Corp. (TSE:QIPT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Quipt Home Medical Corp., Annual General Meeting, Mar 27, 2024

Quipt Home Medical Corp. to Report Q1, 2024 Results on Feb 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Quipt Home Medical Corp. to Report Q4, 2023 Results on Dec 18, 2023

Now 21% undervalued after recent price drop

What Is Quipt Home Medical Corp.'s (TSE:QIPT) Share Price Doing?

Consensus EPS estimates fall by 97%

Calculating The Fair Value Of Quipt Home Medical Corp. (TSE:QIPT)

Consensus EPS estimates fall by 98%

Third quarter 2023 earnings: EPS misses analyst expectations

Quipt Home Medical Corp.(TSXV:QIPT) dropped from S&P/TSX Venture Composite Index

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 80%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 19%

Consensus EPS estimates fall by 20%

We Think Quipt Home Medical's (CVE:QIPT) Robust Earnings Are Conservative

Consensus EPS estimates increase by 37%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Quipt Home Medical Corp., Annual General Meeting, Mar 24, 2023

Consensus revenue estimates increase by 21%

Investor sentiment improved over the past week

Consensus EPS estimates fall by 47%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Earnings Update: Quipt Home Medical Corp. (CVE:QIPT) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Consensus forecasts updated

Health Check: How Prudently Does Quipt Home Medical (CVE:QIPT) Use Debt?

Quipt Home Medical Corp. (TSXV : QIPT) acquired Hometown Medical, LLC.

Quipt Home Medical Corp. Reiterates Outlook for 2022

Quipt Home Medical Corp. (TSXV:QIPT) acquired Norcal Respiratory, Inc. for $3.1 million.

When Should You Buy Quipt Home Medical Corp. (CVE:QIPT)?

Second quarter 2022 earnings: EPS exceeds analyst expectations

Quipt Home Medical Corp. Reiterates Revenue Guidance for the First Quarter of Fiscal Year 2023

Quipt Home Medical Corp., Annual General Meeting, Jun 02, 2022

Quipt Home Medical Corp. Provides Earnings Guidance for the First Quarter of Fiscal Year 2023

Quipt Home Medical Corp. Appoints Brian J. Wessel as an Independent Director and Chair of the Audit Committee

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS misses analyst expectations

Quipt Home Medical Corp Receives Letter from Nasdaq Notifying Nom-Compliance

Quipt Home Medical Corp. Reiterates Earnings Guidance for the Fiscal Year 2022

Quipt Home Medical Corp. (TSXV:QIPT) completed the acquisition of At Home Health Equipment, Inc. for approximately $13.1 million.

Quipt Home Medical Corp. Provides Earnings Guidance for the Fiscal Year 2022

Third quarter 2021 earnings released: EPS US$0.20 (vs US$0.12 loss in 3Q 2020)

Quipt Home Medical Corp. (TSXV:QIPT) acquired Medical West Healthcare Center, LLC for $2.4 million.

Forecast breakeven moved forward to 2021

Quipt Home Medical Corp. (CVE:QIPT) Shares Could Be 43% Below Their Intrinsic Value Estimate

Does Protech Home Medical (CVE:PTQ) Have A Healthy Balance Sheet?

Protech Home Medical Corp. (CVE:PTQ) Could Be Less Than A Year Away From Profitability

First quarter 2021 earnings released: EPS US$0.002 (vs US$0.016 loss in 1Q 2020)